Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 4Unspecified Childhood Solid Tumor, Protocol Specific 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 16Dexamethasone 14Melphalan 12Bortezomib 11Filgrastim 6Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Thalidomide 4Prednisone 4sargramostim 3fludarabine phosphate 3daratumumab 3Radiotherapy 3Mycophenolic Acid 3Interferon-alpha 3Doxorubicin 3Busulfan 3Antilymphocyte Serum 3pomalidomide 2isatuximab 2fludarabine 2Vincristine 2Methylprednisolone 2Idarubicin 2Cyclosporine 2Carmustine 2plerixafor 1pegfilgrastim 1orantinib 1epoetin beta 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Plasma Cell × Immunologic Techniques × Clear all
NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Unknown
35 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡